prion protein (Kanno blood group)Genealiases: ASCR · AltPrP · CD230 · CJD · GSS · KURU
Q-omics provides the consensus-scored PRNP profile across patient tissues and cancer cell-line models. PRNP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PRNP is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PRNP protein abundance shows 28,074 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where PRNP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRNP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRNP survival associations across molecular data types. PRNP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRNP RNA expression–survival associations across cancer types. High PRNP expression shows unfavorable associations in UCEC, UVM, COAD, HNSC, KIRP and GBM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PRNP RNA expression.
This table summarizes PRNP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRNP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRNP shows lower tumor expression in LUAD, UCEC, BRCA, BLCA and READ and higher tumor expression in HNSC. The HNSC box plot shows higher PRNP RNA expression in tumor versus normal tissue (log2 FC = +2.546, t-test p < 0.001).
This table shows molecular features associated with PRNP in patient tissues and cancer cell lines. In patient samples, PRNP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRNP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
